Journal Watch 13/11/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
top of page
Browse by category
Search
Nearly two-thirds of people stop taking weight loss drugs due to side effects and cost
The majority of patients prescribed weight loss drugs for obesity stop taking them because of side effects and cost, according to the...
No overall cost–benefit after RYGB versus SG among T2DM patients
Patients with type 2 diabetes (T2DM) at baseline undergoing RYGB appear to experience a reduced need for ambulatory T2DM monitoring and...
Low adherence and increased cost in first year of taking GLP-1a drugs for weight loss
An analysis of real-world integrated pharmacy and medical claims data by leading pharmacy benefit manager Prime Therapeutics and Magellan...
Half the global population will be living with overweight and obesity by 2035
The World Obesity Atlas 2023, published by World Obesity Federation, has estimated that more than half the global population will be...
Journal Watch 4/01/2023
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Annual costs of rising overweight and obesity rates estimated at US$2.2 trillion
A study has predicted that US$2.2 trillion could be saved annually if overweight and obesity (OAO) prevalence remained at 2019 levels....
No significant difference between costs, mortality and re-admissions between RYGB and SG
Researchers from Canada have reported that four-year health care expenditures, all-cause mortality, and number of hospital admissions...
Browse by tag
bottom of page